TGBA01AD

TGBA01AD
Clinical data
Other names	FKB01MD
Routes of; administration	By mouth
Pharmacokinetic data
Bioavailability	17%
Elimination half-life	4 hours
Chemical and physical data
3D model (JSmol)	Interactive image;
	SMILES OCC1OC(C(O)C1O)C2(O)NC=CC(=O)N2;
	InChI InChI=1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)9(16)10-2-1-5(13)11-9/h1-2,4,6-8,10,12,14-16H,3H2,(H,11,13); Key:QJTQVQQHNGHIKY-UHFFFAOYSA-N;

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT_1A and 5-HT_1D receptor agonist, and 5-HT₂ receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.^[2]^[1] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.^[3]

References[]

^ ^a ^b ^c "FKB01MD". Fabre-Kramer.
^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
^ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[FabreKramer2015-1] "FKB01MD". Fabre-Kramer.

[PharmaMed2013-2] "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.

[AdisInsight-3] "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]

[3]

Clinical data
Other names	FKB01MD
Routes of administration	By mouth
Pharmacokinetic data
Bioavailability	17%^[1]
Elimination half-life	4 hours^[1]
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES OCC1OC(C(O)C1O)C2(O)NC=CC(=O)N2
InChI InChI=1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)9(16)10-2-1-5(13)11-9/h1-2,4,6-8,10,12,14-16H,3H2,(H,11,13) Key:QJTQVQQHNGHIKY-UHFFFAOYSA-N

TGBA01AD

See also[]

References[]